🔎 Trials Near Me

Home › Kanser sa Dugo › Wisconsin › Milwaukee

Pag-aaral pangklinika para sa Kanser sa Dugo sa Milwaukee, WI

Isang pag-aaral para sa Kanser sa Dugo ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Milwaukee. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

Nagre-recruitObservasyonal na pag-aaral
  • Aurora Cancer Care-Milwaukee, Milwaukee
  • Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
  • Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
  • at 14 pa
Lahat ng edad · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT04242095

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Aurora Cancer Care-Milwaukee, Milwaukee
  • Aurora Saint Luke's Medical Center, Milwaukee
  • Aurora Sinai Medical Center, Milwaukee
  • at 9 pa
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Nagre-recruitObservasyonal na pag-aaral
  • Children's Hospital of Wisconsin, Milwaukee
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Nagre-recruitPhase 3
  • Medical College of Wisconsin, Milwaukee
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Nagre-recruitPhase 3
  • Froedtert & Medical College of Wisconsin, Milwaukee
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Nagre-recruitPhase 1
  • Froedtert & Medical College Clinics, Milwaukee
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788

Social Relationships and Accelerated Aging in Hematopoietic Cell Transplant Survivors

Nagre-recruitObservasyonal na pag-aaral
  • Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT04892823

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • Children's Hospital of Wisconsin, Milwaukee
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Nagre-recruitObservasyonal na pag-aaral
  • Children's Hospital of Wisconsin., Milwaukee
Hanggang edad 30 · Lahat ng kasarian · Na-update Hun 18, 2026 · NCT06579469

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Nagre-recruitPhase 1
  • Medical College of Wisconsin Cancer Center, Milwaukee
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

CIBMTR Research Database

Nagre-recruitObservasyonal na pag-aaral
  • Medical College of Wisconsin, Milwaukee
Lahat ng edad · Lahat ng kasarian · Na-update Ago 12, 2025 · NCT01166009

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Nagre-recruitPhase 1
  • Children's Hospital of Wisconsin, Milwaukee
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770

Pag-aaral para sa Kanser sa Dugo sa ibang lungsod

Iba pang pag-aaral sa Milwaukee

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.